EBioMedicine, Journal Year: 2022, Volume and Issue: 77, P. 103941 - 103941
Published: March 1, 2022
Language: Английский
EBioMedicine, Journal Year: 2022, Volume and Issue: 77, P. 103941 - 103941
Published: March 1, 2022
Language: Английский
Science, Journal Year: 2021, Volume and Issue: 374(6574)
Published: Dec. 16, 2021
T cells play a central role in cancer immunotherapy, but we lack systematic comparison of the heterogeneity and dynamics tumor-infiltrating across types. We built single-cell RNA-sequencing pan-cancer atlas for 316 donors 21 types revealed distinct cell composition patterns. found multiple state-transition paths exhaustion CD8+ preference those among different tumor Certain populations showed specific correlation with patient properties such as mutation burden, shedding light on possible determinants microenvironment. compositions within tumors alone could classify patients into groups clinical trait specificity, providing new insights immunity precision immunotherapy targeting cells.
Language: Английский
Citations
860Immunity, Journal Year: 2020, Volume and Issue: 52(5), P. 825 - 841.e8
Published: May 1, 2020
Language: Английский
Citations
738Cancer Cell, Journal Year: 2020, Volume and Issue: 37(4), P. 443 - 455
Published: April 1, 2020
Language: Английский
Citations
665Cancer Discovery, Journal Year: 2021, Volume and Issue: 11(4), P. 838 - 857
Published: April 1, 2021
Immune checkpoint therapy (ICT) can provide durable clinical responses and improve overall survival. However, only subsets of patients with specific tumor types respond to ICT. Thus, significant challenges remain, including understanding pathways resistance, optimizing patient selection, improving management immune-related adverse events, identifying rational therapeutic combinations. These will need a focused approach encompassing both basic research, the integration reverse translational studies. This integrated lead identification potential targets for subsequent trials, which guide decisions as we develop novel combination strategies maximize efficacy minimize toxicities patients. SIGNIFICANCE: ICTs induce antitumor cancer. Recent evidence suggests that combinatorial response by overcoming primary adaptive resistance mechanisms, although these may carry an increased risk immune-mediated toxicities. review surveys current mechanisms active areas investigation, proposes path forward minimizing through better selection
Language: Английский
Citations
545Nature Reviews Drug Discovery, Journal Year: 2020, Volume and Issue: 19(11), P. 776 - 800
Published: Sept. 14, 2020
Language: Английский
Citations
454Science, Journal Year: 2021, Volume and Issue: 372(6537)
Published: April 1, 2021
CAR-T cells rest to get back in the race Chimeric antigen receptor (CAR)–T cells, which are engineered target specific tumor antigens, increasingly used as an immunotherapy. have shown promising results patients, particularly hematologic cancers, but their anticancer activity can be limited by onset of exhaustion and loss effectiveness. Weber et al. characterized phenotypic epigenomic changes associated with cell caused continuous beneficial effects transient periods (see Perspective Mamonkin Brenner). The authors tested different approaches for providing these periods, such using drug dasatinib temporarily suppress T activity, helped prevent improved antitumor mouse models. Science , this issue p. eaba1786 ; see also 34
Language: Английский
Citations
453Nature Communications, Journal Year: 2021, Volume and Issue: 12(1)
Published: Feb. 5, 2021
The two T cell inhibitory receptors PD-1 and TIM-3 are co-expressed during exhausted differentiation, recent evidence suggests that their crosstalk regulates exhaustion immunotherapy efficacy; however, the molecular mechanism is unclear. Here we show contributes to persistence of
Language: Английский
Citations
423Immunity, Journal Year: 2020, Volume and Issue: 54(1), P. 99 - 115.e12
Published: Dec. 2, 2020
Language: Английский
Citations
407Nature Immunology, Journal Year: 2020, Volume and Issue: 21(12), P. 1540 - 1551
Published: Oct. 5, 2020
Language: Английский
Citations
391Nature reviews. Immunology, Journal Year: 2021, Volume and Issue: 21(12), P. 785 - 797
Published: April 29, 2021
Language: Английский
Citations
384